{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["2(2)"],"submitter":["Haninger-Vacariu N"],"pubmed_abstract":["In patients with pregnancy-associated complement gene variant-mediated thrombotic microangiopathy (cTMA), terminal complement blockade is used for treatment of cTMA flares during pregnancy or following delivery. We report pregnancy and delivery outcomes of 2 genetically high-risk patients with cTMA, including 1 kidney transplant recipient, during ongoing eculizumab therapy. In both patients, the first manifestation of cTMA occurred independent from pregnancy. One patient has a history of 2 uneventful pregnancies with prophylactic plasma infusions, and the other has a history of early abortion during long-term eculizumab therapy following kidney transplantation. Overall, pregnancy and delivery outcomes under ongoing eculizumab therapy in our 2 patients with preserved kidney function were ex"],"journal":["Kidney medicine"],"pagination":["213-217"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7380370"],"repository":["biostudies-literature"],"pubmed_title":["Successful Pregnancies During Ongoing Eculizumab Therapy in Two Patients With Complement-Mediated Thrombotic Microangiopathy."],"pmcid":["PMC7380370"],"pubmed_authors":["Piggott LC","Haninger-Vacariu N","Gaggl M","Aigner C","Sunder-Plassmann R","Schmidt A","Prohaszka Z","Bohmig GA","Sunder-Plassmann G","Kain R"],"additional_accession":[]},"is_claimable":false,"name":"Successful Pregnancies During Ongoing Eculizumab Therapy in Two Patients With Complement-Mediated Thrombotic Microangiopathy.","description":"In patients with pregnancy-associated complement gene variant-mediated thrombotic microangiopathy (cTMA), terminal complement blockade is used for treatment of cTMA flares during pregnancy or following delivery. We report pregnancy and delivery outcomes of 2 genetically high-risk patients with cTMA, including 1 kidney transplant recipient, during ongoing eculizumab therapy. In both patients, the first manifestation of cTMA occurred independent from pregnancy. One patient has a history of 2 uneventful pregnancies with prophylactic plasma infusions, and the other has a history of early abortion during long-term eculizumab therapy following kidney transplantation. Overall, pregnancy and delivery outcomes under ongoing eculizumab therapy in our 2 patients with preserved kidney function were ex","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Mar-Apr","modification":"2025-04-21T17:01:54.484Z","creation":"2025-04-21T17:01:54.484Z"},"accession":"S-EPMC7380370","cross_references":{"pubmed":["32734241"],"doi":["10.1016/j.xkme.2019.12.004"]}}